

**► BIOPHARMA POOL****Mark Alles**
Dr. Jacquelyn Fouse
Bob Hugin
Scott Smith**CELGENE STRENGTHENS LEADERSHIP TEAM****Mark Alles**

Celgene has made several organizational changes to strengthen its leadership team and position the company for long-term growth.

Mark Alles has been promoted to CEO. Mr. Alles is a three-decade industry veteran and has been with Celgene since 2004, most recently serving as president and chief operating officer during which time he integrated Celgene's corporate operational functions in support of its global commercial franchises. Before serving as president and chief operating officer, he built and led Celgene's hematology and oncology franchise.

Jacquelyn Fouse, Ph.D., has been promoted to president and chief operating officer (COO). Dr. Fouse joined Celgene in 2010 as chief financial officer and has excelled as both the leader of Celgene's finance department and in her current role as president of Celgene's hematology and oncology franchise. Dr. Fouse is charged with further enhancing Celgene's commitment to operational excellence and driving exceptional performance across Celgene's franchises and functions.

Bob Hugin has been named executive chairman. He continues to lead the board of directors and manage the strategic direction of the company.

Scott Smith, president of Celgene's I&I franchise, has been appointed to chair Celgene's global management committee, where he is responsible for the effective coordination of Celgene's operational and strategic imperatives.

Rinko Ghosh
SYMIC NAMES PRESIDENT AND CHIEF BUSINESS OFFICER**Rinko Ghosh**

Symic, a clinical-stage biopharmaceutical company developing multiple compounds that target and affect the extracellular matrix (ECM), has appointed Rinko Ghosh as president and chief business officer.

Previously, Mr. Ghosh was senior VP and chief business officer at Nektar Therapeutics.

Dr. Richard McCloskey
RENOVA THERAPEUTICS APPOINTS LEAD FOR CLINICAL DEVELOPMENT

Richard "Mac" McCloskey, M.D., joins Renova Therapeutics as executive VP of clinical development

**Dr. McCloskey**

responsible for all clinical aspects of the company's trials, including preparation of trial synopses and protocols, review and approval of case report systems and safety reporting, and drafting of clinical trial endpoints. Renova Therapeutics is a biopharmaceutical company developing gene therapy treatments for congestive heart failure and other chronic diseases.

Chris Rivera
NATIVIS NAMES NEW CHAIRMAN, PRESIDENT, AND CEO**Chris Rivera**

Nativis, a clinical-stage bioelectronics company developing non-invasive therapies for cancers and other serious diseases, has named Chris Rivera chairman, president, and CEO. Mr. Rivera has served as a director of the company since 2013 and brings 30 years of biotechnology industry experience to Nativis.

Mr. Rivera's career highlights include founder and CEO of Hyperion Therapeutics, which was acquired by Horizon Pharma in 2015.

Mary Szela
AGERION PHARMACEUTICALS NAMES CEO**Mary Szela**

Agerion Pharmaceuticals, a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, has appointed Mary Szela CEO. Ms. Szela brings 27 years of progressive leadership experience to Agerion as well as valuable expertise building global billion-dollar brands, such as Humira, and advancing pipeline products in the biotechnology and pharmaceutical industries. Most recently, Ms. Szela was CEO of Melinta Therapeutics.

► SPECIALTY POOL**Dr. Indranil Nandi**
VERTICE PHARMA APPOINTS VP, RESEARCH & DEVELOPMENT**Dr. Indranil Nandi**

Vertice Pharma, a specialty pharmaceuticals company focused on improving patients' health, has appointed Indranil Nandi, Ph.D., as VP, research and development. Most recently, Dr. Nandi has served as VP, generic R&D, for Impax Laboratories.

Jeff Mihm
NOVEN APPOINTS CEO**Jeff Mihm**

Jeff Mihm has been appointed Noven's CEO, succeeding Jeffrey Eisenberg. Mr. Mihm joined Noven in 2003 and since then has been consistently promoted to senior leadership positions of increasing scope and importance. Most recently,

he served as VP, chief administrative officer and general counsel, where he oversaw Noven's business development, corporate affairs, human resources, information technology, and legal/compliance functions.

Noven is a specialty pharmaceutical company engaged in the research, development, manufacturing, marketing and sale of prescription pharmaceutical products.

► AGENCY POOL**Bill McEllen**
FINGERPAINT TAPS AGENCY VETERAN FOR NY OFFICE**Bill McEllen**

Fingerpaint, a full-service marketing agency, has appointed Bill McEllen to lead its New York office. Mr. McEllen brings more than 20 years of experience in client-side sales, marketing, and advertising, as well as an innate ability to combine corporate objectives with creative strategies to produce impactful campaigns. Mr. McEllen joins Fingerpaint after 13 years with McCann where he served as president of both the Torre Lazur and Echo Torre Lazur Groups.

Horacio Rodriguez
ASHFIELD ADDS TO LEADERSHIP TEAM**Horacio Rodriguez**

Ashfield, part of UDG Healthcare, has named Horacio Rodriguez VP of clinical and commercial contact center US in its Ivyland, Pa., office. Mr. Rodriguez has more than 25 years of commercial healthcare experience in pharmaceutical sales, brand marketing, and contact center management within oncology, neurology, endocrinology, gastroenterology, cardiovascular, and asthma. He was VP of healthcare commercial and medical operations US for TeleRx. ^{PV}



FOR BONUS CONTENT
USE YOUR QR CODE READER
OR GO TO
bit.ly/PV0316-Pool



► BIOPHARMA POOL

Rowena Choudrie
Kevin Zikaras

ACTINIUM PHARMACEUTICALS ANNOUNCES NEW HIRES TO PRODUCT DEVELOPMENT AND CLINICAL RESEARCH TEAMS

Actinium Pharmaceuticals, a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, has appointed Rowena Choudrie to the position of senior director, pharmaceutical product development, and Kevin Zikaras to the position of senior clinical scientist.

Ms. Choudrie has more than 20 years of pharmaceutical industry experience with roles of increasing responsibility in product development. Most recently, Ms. Choudrie worked at NPS Pharmaceuticals as senior director, pharmaceutical development, global technical operations.

Mr. Zikaras joins Actinium from Bristol-Myers Squibb where he was a clinical protocol manager in the Immuno-Oncology group since 2014.

Dr. Craig Granowitz
Dr. Steven Ketchum

AMARIN ADDS TO SENIOR MANAGEMENT

Amarin, a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, has appointed Craig Granowitz, M.D., Ph.D., to the position of chief medical officer. In this role, Dr. Granowitz is providing strategic and operational leadership across multiple functions, including medical affairs, drug safety, and medical communications. In addition, the title and role of Steven Ketchum, Ph.D., Amarin's president of research and development and senior VP, has been expanded to include the responsibility of chief scientific officer.

Before joining Amarin, Dr. Granowitz was senior VP and head of global medical affairs, global human health at Merck.

Before joining Amarin, Dr. Ketchum served as senior VP, research and development, for Sunesis Pharmaceuticals.

Marion McCourt
MEDIATION NAMES CHIEF OPERATING OFFICER

Marion McCourt has joined Medivation, a biopharmaceutical company focused on the development and commercialization of medically innovative therapies to treat serious diseases for which there are limited treatment options, as chief operating officer.

In this newly created position, Ms. McCourt is responsible for oversight of several functions, including commercial operations, medical affairs, manufacturing, quality, and corporate efficiency.

Most recently, she was VP in U.S. commercial operations for Amgen.

Dr. James Owen
ACADIA PHARMACEUTICALS APPOINTS SENIOR VP, CLINICAL DEVELOPMENT AND CHIEF MEDICAL OFFICER

Acadia Pharmaceuticals, a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, has appointed James (Randy) Owen, M.D., as senior VP, clinical development and chief medical officer. Dr. Owen is responsible for evolving and executing the clinical development programs for the company's product candidates.

Dr. Owen most recently served as VP, U.S. clinical affairs, at Lundbeck LLC, from 2010 to 2016.

► BIOTECH POOL

Dr. Christopher Silber
AGILIS BIOTHERAPEUTICS NAMES CHIEF MEDICAL OFFICER

Agilis Biotherapeutics, a biotechnology company advancing innovative gene therapy products for the treatment of rare genetic diseases that affect the central nervous system, has appointed Christopher Silber, M.D., as chief medical officer. Dr. Silber has more than 25 years of clinical development leadership experience in the pharmaceutical industry, including orphan drug development, with extensive therapeutic experience in neuroscience. Before joining Agilis, he spent seven years at H. Lundbeck A/S.

Dr. Jeffrey Stoddard
NOVAVAX APPOINTS VP, MEDICAL AFFAIRS

Novavax, a clinical-stage vaccine company focused on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants, has appointed Jeffrey Stoddard, M.D., to the position of VP, medical affairs. Dr. Stoddard's efforts are focused on external engagement with thought leaders, vaccine experts, policymakers, and key stakeholders. He is also responsible for evidence generation related to health economics and outcomes research.

Dr. Stoddard joins Novavax with more than 15 years of vaccine research and development experience and leadership roles and was most recently VP, medical affairs and medical professional services, at Alkermes.

► SPECIALTY POOL

Sherry Korczynski
EAGLE PHARMACEUTICALS NAMES SENIOR VP OF MARKETING

Eagle Pharmaceuticals has named Sherry

Korczynski as senior VP of marketing. She joins Eagle from Mylan Specialty, where she was VP of EpiPen marketing.

► CRO POOL

Dr. Cynthia Berger
AVERICA APPOINTS VP OF OPERATIONS

Averica Discovery, an analytical development contract research organization with specialized expertise in small-molecule analysis and purification, has appointed Cynthia Berger, Ph.D., to the newly created position of VP of operations.

Before joining Averica Discovery, Dr. Berger served as project manager at PCI Synthesis, a contract manufacturing organization (CMO), where she managed multimillion dollar projects manufacturing active pharmaceutical ingredients.

► AGENCY POOL

Dr. John Hixson
FRESHBLOOD HEALTH MARKET NAMES SENIOR MEDICAL DIRECTOR/NEUROLOGIST

FreshBlood Health Market Consultants, an on-demand creative consultancy comprised of senior-level management consultants and communications specialists in the healthcare industry, expanded its clinical capabilities and scientific expertise with the addition of highly regarded neurologist, John Hixson, M.D., as a senior medical director/neurologist.

Dr. Hixson is an accomplished clinical neurologist, associate professor at the University of California San Francisco, American Academy of Neurology Committee member, published author, and public speaker who holds a degree from the Johns Hopkins University School of Medicine.

► CONSULTING POOL

Dr. Mark Weinberg
HALLORAN CONSULTING GROUP ADDS CHIEF MEDICAL OFFICER

Halloran Consulting Group has expanded its strategic capabilities with the addition of Mark Weinberg, M.D., who serves as chief medical officer and managing director. The addition of Dr. Weinberg to Halloran's advisory services creates a unique offering to life-sciences companies seeking CMO expertise as a key part of an on-demand, integrated development team. Before joining Halloran, Dr. Weinberg worked at RestorGenex as senior VP and head of development. 



The world of health care is evolving right before our eyes.

DIA puts YOU at the forefront of these changes through its conferences, training, online learning, publications, and membership.

Marketing Pharmaceuticals 2016

Tutorial (PM): March 2 | Conference: March 3-4 | North Bethesda, MD

Understand the complexity of marketing and how to promote products in an effective yet compliant manner. Topics will cover FDA updates on recent enforcement actions and guidances, engaging payors, nontraditional, and emerging customer markets, advocacy groups: when & how should they be engaged, and more.

Visit DIAglobal.org/MarketingPharma for more information.

Medical Affairs and Scientific Communications 2016 Annual Forum

Core Curriculum: March 20 | Tutorials (AM): March 21

Forum: March 21-23 | Kissimmee, FL

Every March, DIA brings together Medical Affairs professionals from the Medical Communications, Medical Information, Medical Writing, and Medical Science Liaison areas to network, collaborate, and expand their expertise.

Visit DIAglobal.org/MSA for more information.

DIA 2016

Tutorials: June 26 | Meeting: June 27-30 | Philadelphia, PA

The DIA Annual Meeting is our largest interdisciplinary event, bringing together a global network of 7,000+ life sciences professionals from industry, academia, regulatory and government agencies, and patient and philanthropic organizations, to foster innovation that leads to the development of safe and effective products and therapies to patients.

Visit DIAglobal.org/DIA2016 for more information.

*Build a Global Network.
Develop Your Career.
Enhance Your
Knowledge.*

DIA Membership gives you opportunities for collaboration with top leaders, resources to advance your career, and a powerful network to expand your knowledge across disciplines.

DIA offers 30+ Communities:

- Medical Writing
- Medical Communications
- Medical Science Liaisons
- Regulatory Affairs
- Plus Many More

*Join DIA today.
Visit DIAglobal.org*